Olivier Meilhac

University of La Réunion, Saint-Denis, Réunion, Reunion

Are you Olivier Meilhac?

Claim your profile

Publications (140)612.73 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Albumin, the major circulating protein in blood plasma, can undergo increased glycation in a diabetes context. Albumin exerts crucial pharmacological activities through its drug binding capacity, i.e ketoprofen, and via its esterase-like activity enabling the conversion of pro-drugs into active drugs. In this study, the impact of the glucose-mediated glycation on the pharmacological and biochemical properties of human albumin was investigated. Aggregation product levels and redox state were quantified to assess the impact of glycation-mediated changes on the structural properties of albumin. Glucose-mediated changes in ketoprofen-binding properties and esterase-like activity were evaluated using fluorescence spectroscopy and p-nitrophenyl acetate hydrolysis assays, respectively. With the exception of oxidative parameters, significant dose-dependent alterations in biochemical and functional properties of in vitro glycated albumin were observed. We also found that the dose-dependent increase in levels of glycation, protein aggregation and average molecular mass changes correlated with a gradual decrease in albumin affinity for ketoprofen and its esterase-like property. In parallel, significant alterations in both pharmacological properties were also evidenced in albumin purified from diabetic patients. Partial least squares regression analyses established a significant correlation between glycation-mediated changes in biochemical and pharmacological properties of albumin, highlighting the important role for glycation in the variability of drug response under diabetic situation.
    Biochemistry 04/2015; 54(19):150427182221002. DOI:10.1021/acs.biochem.5b00273 · 3.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abdominal aortic aneurysm (AAA) evolution is unpredictable, and there is no therapy except surgery for patients with an aortic size> 5 cm (large AAA). We aimed to identify new potential biomarkers that could facilitate prognosis and treatment of patients with AAA. A differential quantitative proteomic analysis of plasma proteins was performed in AAA patients at different stages of evolution [small AAA (aortic size=3-5cm) vs large AAA] using iTRAQ labelling, high-throughput nano-LC-MS/MS and a novel multi-layered statistical model. Among the proteins identified, ApoA-I was decreased in patients with large AAA compared to those with small AAA. These results were validated by ELISA on plasma samples from small (n=90) and large AAA (n=26) patients (150± 3 vs 133± 5 mg/dl, respectively, p< 0.001). ApoA-I levels strongly correlated with HDL-Cholesterol (HDL-C) concentration (r=0.9, p< 0.001) and showed a negative correlation with aortic size (r=-0.4, p< 0.01) and thrombus volume (r=-0.3, p< 0.01), which remained significant after adjusting for traditional risk factors. In a prospective study, HDL-C independently predicted aneurysmal growth rate in multiple linear regression analysis (n=122, p=0.008) and was inversely associated with need for surgical repair (Adjusted hazard ratio: 0.18, 95 % confidence interval: 0.04-0.74, p=0.018). In a nation-wide Danish registry, we found lower mean HDL-C concentration in large AAA patients (n=6,560) compared with patients with aorto-iliac occlusive disease (n=23,496) (0.89± 2.99 vs 1.59± 5.74 mmol/l, p< 0.001). Finally, reduced mean aortic AAA diameter was observed in AngII-infused mice treated with ApoA-I mimetic peptide compared with saline-injected controls. In conclusion, ApoA-I/HDL-C systemic levels are negatively associated with AAA evolution. Therapies targeting HDL functionality could halt AAA formation.
    Thrombosis and Haemostasis 03/2015; 113(6). DOI:10.1160/TH14-10-0874 · 5.76 Impact Factor
  • International journal of cardiology 03/2015; 184:724-727. DOI:10.1016/j.ijcard.2015.03.035 · 6.18 Impact Factor
  • Diabetes & Metabolism 03/2015; 41:A58. DOI:10.1016/S1262-3636(15)30215-9 · 2.85 Impact Factor
  • Olivier Meilhac
    [Show abstract] [Hide abstract]
    ABSTRACT: Besides their well-documented function of reverse transport of cholesterol, high-density lipoproteins (HDLs) display pleiotropic effects due to their antioxidant, antithrombotic, anti-inflammatory and antiapoptotic properties that may play a major protective role in acute stroke, in particular by limiting the deleterious effects of ischaemia on the blood-brain barrier (BBB) and on the parenchymal cerebral compartment. HDLs may also modulate leukocyte and platelet activation, which may also represent an important target that would justify the use of HDL-based therapy in acute stroke. In this review, we will present an update of all the recent findings in HDL biology that could support a potential clinical use of HDL therapy in ischaemic stroke.
    Handbook of experimental pharmacology 01/2015; 224:509-526. DOI:10.1007/978-3-319-09665-0_16
  • International Journal of Nanotechnology 01/2015; 12(8/9):552. DOI:10.1504/IJNT.2015.068877 · 1.14 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective Previous studies have suggested positive associations between periodontal infection and cardiovascular disease. We aimed to investigate the associations of circulating antibodies against periodontal pathogens with 1-year cardiovascular outcome, as well as the extent of coronary atherosclerosis, plaque vulnerability and lesion remodeling on intravascular ultrasound (IVUS) imaging. Methods Between 2008 and 2011, radiofrequency IVUS imaging of a non-culprit coronary artery was performed in 581 patients who underwent coronary angiography. Immunoglobulin G (IgG) and A (IgA) against Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, Tannerella forsythia and Prevotella intermedia were measured in plasma. Results None of the antibody levels were associated with coronary plaque burden, radiofreqeuncy-IVUS-derived thin-cap fibroatheroma lesion morphology or 1-year incidence of major adverse cardiac events (MACE), which included all-cause mortality, acute coronary syndrome and unplanned coronary revascularization. IgA against A. actinomycetemcomitans, T. forsythia and P. intermedia were inversely associated with extent of positive lesion remodeling (OR for highest versus lowest tertile 0.55, 95%CI 0.35–0.88, p = 0.012; 0.53, 95%CI 0.32–0.87, p = 0.012; and 0.64, 95%CI 0.40–1.02, p = 0.061, respectively). In diabetic patients specifically, IgG against P. gingivalis tended to be associated with coronary plaque burden (p = 0.080), while IgA against P. gingivalis tended to be associated with incident MACE (p = 0.060). Conclusion Plasma IgG and IgA against major periodontal pathogens were not associated with the extent of coronary atherosclerosis (with the exception of a trend in diabetics) nor with coronary plaque vulnerability. IgA against periodontal pathogens were inversely associated with extent of coronary remodeling. Altogether, these results do not add evidence for a substantial role of systemic exposure to periodontal pathogens in coronary artery disease.
    Atherosclerosis 11/2014; 237(1):84–91. · 3.97 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective Epidemiological, biological and clinical links between periodontal and cardiovascular diseases are now well established. Several human studies have detected bacterial DNA corresponding to periodontal pathogens in cardiovascular samples. Intraplaque hemorrhage has been associated with a higher risk of atherosclerotic plaque rupture, potentially mediated by neutrophil activation. In this study, we hypothesized that plaque composition may be related to periodontal pathogens. Methods Carotid culprit plaque samples were collected from 157 patients. Macroscopic characterization was performed at the time of collection: presence of blood, lipid core, calcification and fibrosis. Markers of neutrophil activation released by carotid samples were quantified (myeloperoxidase or MPO, cell-free DNA and DNA-MPO complexes). PCR analysis using specific primers for Porphyromonas gingivalis, Aggregatibacter actinomycetemcommitans, Treponema denticola, Prevotella intermedia and Tannerella forsythia was used to detect DNA from periodontal pathogens in carotid tissues. In addition, bacterial lipopolysaccharide (LPS) and Immunoglobulins G against Tannerella forsythia were quantified in atherosclerotic carotid conditioned medium. Results Intraplaque hemorrhage was present in 73/157 carotid samples and was associated with neutrophil activation, reflected by the release of MPO, cell-free DNA and MPO-DNA complexes. LPS levels were also linked to intraplaque hemorrhage but not with the neutrophil activation markers. Seventy-three percent of the carotid samples were positive for periodontal bacterial DNA. Furthermore, hemoglobin levels were associated with the detection of T. forsythia and neutrophil activation/inflammation markers. Conclusion This study suggests a potential role of periodontal microorganisms, especially T. forsythia, in neutrophil activation within hemorrhagic atherosclerotic carotid plaques.
    Atherosclerosis 10/2014; 236(2). DOI:10.1016/j.atherosclerosis.2014.07.034 · 3.97 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Previous studies have suggested positive associations between periodontal infection and cardiovascular disease. We aimed to investigate the associations of circulating antibodies against periodontal pathogens with 1-year cardiovascular outcome, as well as the extent of coronary atherosclerosis, plaque vulnerability and lesion remodeling on intravascular ultrasound (IVUS) imaging.
    Atherosclerosis 09/2014; 237(1):84-91. DOI:10.1016/j.atherosclerosis.2014.08.050 · 3.97 Impact Factor
  • Annales Françaises d Anesthésie et de Réanimation 09/2014; 33:A172-A173. DOI:10.1016/j.annfar.2014.07.289 · 0.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abdominal aortic aneurysm (AAA) is a particular form of arterial disease characterized by the dilation of the aortic wall and the presence of an intraluminal thrombus linked to a high proteolytic activity. The aim of this study was to investigate the effect of an elastase inhibitor (AZD9668 from AstraZeneca) on aneurysm progression.
    Journal of Vascular Surgery 08/2014; DOI:10.1016/j.jvs.2014.07.102 · 2.98 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background and Purpose-Low levels of low-density lipoprotein-cholesterol (LDL-C) are suspected to be associated with a risk of hemorrhagic transformation after ischemic stroke. We assessed the risk of hemorrhagic transformation after cerebral ischemia/reperfusion in mice with low levels of LDL-C resulting from proprotein convertase subtilisin kexin 9 (PCSK9) deficiency. Methods-PCSK9(-/-) and PCSK9(+/+) mice were fed with a high-fat/high-cholesterol (21%/0.15%) diet for 1 month. Plasma lipids were measured using colorimetric assays. PCSK9(-/-) and PCSK9(+/+) mice (n=15 per group) were subjected to a 4-hour intraluminal occlusion of the middle cerebral artery followed by 20 hours of reperfusion. Spontaneous hemorrhagic transformation was assessed by quantification of hemoglobin in ischemic tissue. In vitro, a cell model of blood-brain barrier was used to test endothelial barrier integrity in response to decreasing concentrations of LDL-C from 1 to 0.25g/L in ischemia/reperfusion conditions. Results-PCSK9(-/-) mice had lower LDL-C, high-density lipoprotein-cholesterol, and total cholesterol levels than PCSK9(+/+) mice before and after 1 month on the high-fat/high-cholesterol diet. Hemoglobin concentration in ischemic cerebral tissue was not different between PCSK9(-/-) and PCSK9(+/+) mice (31.5 [18.9-60.1] and 32.8 [14.7-69.9] ng/mg protein, respectively; P=0.81). Infarct volume was also similar in both groups (P=0.66). Incubation of human cerebral endothelial cells with decreasing concentrations of LDL-C under ischemia/reperfusion conditions did not alter blood-brain barrier permeability. Conclusions-Low levels of LDL-C did not increase the risk of hemorrhagic transformation after cerebral ischemia/reperfusion in mice. Our observations suggest that PCSK9 inhibition, leading to LDL-C lowering, should not increase hemorrhagic complications after acute ischemic stroke.
    Stroke 08/2014; 45(10). DOI:10.1161/STROKEAHA.114.005958 · 6.02 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rationale: Several studies report that high-density lipoproteins (HDL) can carry alpha1-antitrypsin (AAT, an elastase inhibitor). Objectives: We aimed at determining whether injection of exogenous HDL, enriched or not in AAT, may have protective effects against pulmonary emphysema. Methods: After tracheal instillation of saline or elastase, mice were randomly treated intravenously with saline, human plasma HDL (75mg ApoA1/kg), HDL-AAT (75mg ApoA1-3.75mgAAT/kg) or AAT alone (3.75mg/kg) at 2, 24, 48 and 72h. Results: We have shown that HDL-AAT reached the lung and prevented the development of pulmonary emphysema by 59.3% at 3 weeks (alveoli mean chord length µm: 22.9±2.8 vs 30.7±4.5 μm, p<0.001) whereas injection of HDL or AAT alone only showed a moderate, non-significant protective effect (28.2±4.2 vs 30.7±5μm, p=0.23; and 27.3±5.66 vs 30.71±4.96 μm, p=0.18, respectively). Indeed, protection by HDL-AAT was significantly higher than that observed with HDL or AAT (p=0.006 and p=0.048, respectively). This protective effect was associated (at 6, 24 and 72 hours) with 1) a reduction in neutrophil and macrophage number in the bronchoalveolar lavage fluid (BALF), 2) decreased concentrations of interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and tumor necrosis factor-α (TNF-α) in both BALF and plasma, 3) a reduction in matrix metalloproteinase (MMP)-2 and MMP-9 activities, and 4) a reduction in the degradation of fibronectin, a marker of tissue damage. Also, HDL-AAT reduced acute cigarette smoke-induced inflammatory response. Conclusions: i.v. HDL-AAT treatment afforded a better protection against elastase-induced pulmonary emphysema than AAT alone, and may represent a significant development for the management of emphysema associated with AAT deficiency.
    American Journal of Respiratory Cell and Molecular Biology 05/2014; DOI:10.1165/rcmb.2013-0103OC · 4.11 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective To identify circulating biomarkers that originate from atherosclerotic vulnerable plaques and that could predict future cardiovascular events. Methods After a protein enrichment step (combinatorial peptide ligand library approach), we performed a two-dimensional electrophoresis comparative analysis on human carotid plaque protein extracts (fibrotic and hemorrhagic atherosclerotic plaques). In silico analysis of the biological processes was applied on proteomic data. Luminex xMAP assays were used to quantify inflammatory components in carotid plaques. The systemic quantification of proteins originating from vulnerable plaques in blood samples from patients with stable and unstable coronary disease was evaluated. Results A total of 118 proteins are differentially expressed in fibrotic and hemorrhagic plaques, and allowed the identification of three biological processes related to atherosclerosis (platelet degranulation, vascular autophagy and negative regulation of fibrinolysis). The multiplex assays revealed an increasing expression of VEGF, IL-6, IL-8, IP-10 and RANTES in hemorrhagic as compared to fibrotic plaques (p < 0.05). Measurement of protein expressions in plasmas from patients with stable and unstable coronary disease identified a combination of biomarkers, including proteins of the smooth muscle cell integrity (Calponin-1), oxidative stress (DJ-1) and inflammation (IL-8), that allows the accurate classification of patients at risk (p = 0.0006). Conclusion Using tissue protein enrichment technology, we validated proteins that are differentially expressed in hemorrhagic plaques as potential circulating biomarkers of coronary patients. Combinations of such circulating biomarkers could be used to stratify coronary patients.
    Atherosclerosis 04/2014; 233(2):551–558. DOI:10.1016/j.atherosclerosis.2013.12.019 · 3.97 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Previous proteomics experiments have demonstrated that several proteins are differentially expressed in vulnerable human carotid plaques compared with stable plaques. This study aims to investigate the prognostic value of 13 such circulating biomarkers in patients with coronary artery disease. Between 2008 and 2011, 768 patients who underwent coronary angiography for acute coronary syndrome or stable angina pectoris were included in a prospective biomarker study. Plasma concentrations of 13 biomarkers were measured in 88 patients who experienced a major adverse cardiovascular event (MACE) within 1 year and 176 control patients without MACE who were matched on age, sex, and number of diseased coronary vessels. MACE comprised all-cause mortality, acute coronary syndrome, unplanned coronary revascularization, and stroke. After adjustment for established cardiovascular risk factors, osteoglycin (OGN; odds ratio per SD increase in ln-transformed OGN, 1.53; 95% confidence interval, 1.11-2.11; P=0.010) and neutrophil gelatinase-associated lipocalin/matrix metalloproteinase 9 (NGAL/MMP9; odds ratio per SD increase in ln-transformed NGAL/MMP9, 1.37; 95% confidence interval, 1.01-1.85; P=0.042) complex were independently associated with MACE during follow-up. These associations were independent of C-reactive protein levels. Adding OGN or NGAL/MMP9 to a model containing conventional risk factors did not significantly improve discriminatory power (OGN: area under receiver operating characteristic curve, 0.75 versus 0.67; NGAL/MMP9: 0.73 versus 0.67) but did significantly improve risk reclassification (OGN: net reclassification index=0.29; 95% confidence interval, 0.05-0.53; P<0.019; NGAL/MMP9: net reclassification index=0.44; 95% confidence interval, 0.20-0.69; P<0.001). Circulating OGN and NGAL/MMP9 complex are promising biomarkers that are expressed in vulnerable atherosclerotic plaques and may have incremental value for prediction of MACE within 1 year after coronary angiography.
    Arteriosclerosis Thrombosis and Vascular Biology 03/2014; 34(5). DOI:10.1161/ATVBAHA.114.303486 · 5.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Iron deposits are observed in tissue of abdominal aortic aneurysm (AAA) patients, although the underlying mechanisms are not completely elucidated. Therefore we explored circulating markers of iron metabolism in AAA patients, and tested if they could serve as biomarkers of AAA. Increased red blood cell (RBC)-borne iron retention and transferrin, transferrin receptor and ferritin expression was observed in AAA tissue compared to control aorta (immunohistochemistry and western blot). In contrast, decreased circulating iron, transferrin, mean corpuscular haemoglobin concentration (MCHC) and haemoglobin concentration, along with circulating RBC count, were observed in AAA patients (aortic diameter >3 cm, n=114) compared to controls (aortic diameter <3 cm, n=88) (ELISA), whereas hepcidin concentrations were increased in AAA subjects (MS/MS assay). Moreover, iron, transferrin and haemoglobin levels were negatively, and hepcidin positively, correlated with aortic diameter in AAA patients. The association of low haemoglobin with AAA presence or aortic diameter was independent of specific risk factors. Moreover, MCHC negatively correlated with thrombus area in another cohort of AAA patients (aortic diameter 3-5 cm, n=357). We found that anaemia was significantly more prevalent in AAA patients (aortic diameter >5 cm, n=8,912) compared to those in patients with atherosclerotic aorto-iliac occlusive disease (n=17,737) [adjusted odds ratio=1.77 (95% confidence interval: 1.61;1.93)]. Finally, the mortality risk among AAA patients with anaemia was increased by almost 30% [adjusted hazard ratio: 1.29 (95% confidence interval: 1.16;1.44)] as compared to AAA subjects without anaemia. In conclusion, local iron retention and altered iron recycling associated to high hepcidin and low transferrin systemic concentrations could lead to reduced circulating haemoglobin levels in AAA patients. Low haemoglobin levels are independently associated to AAA presence and clinical outcome.
    Thrombosis and Haemostasis 03/2014; 112(1). DOI:10.1160/TH13-08-0721 · 5.76 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In this work, we describe an approach of detecting biomarkers by Surface Plasmon Resonance imaging (SPRi) technique in real samples. Two C-Reactive Protein (CRP)-antibody immobilization methods were used: The first method was based on direct physisorption of CRP-antibody onto gold surface; the second one was based on oriented CRP-antibody with protein G intermediate layer. The two developed immunosensors were tested against CRP antigen in phosphate buffer saline solution with the SPRi technique. The response of the developed immunosensors was reproducible and stable. The detection limit of 10 pg∙mL−1 and 50 pg∙mL−1 CRP-antigen was observed with and without protein G respectively with this technique. Moreover, the developed SPRi immunosensor was used for CRP-antigen detection in human plasma. A detection limit of 5 ng∙mL−1 and 10 ng∙mL−1 was obtained with and without protein G respectively. These obtained results were compared to those obtained with QCM (Quartz Crystal Microbalance) and Enzyme-Linked Immunosorbent Assay (ELISA) techniques.
    Journal of Biomaterials and Nanobiotechnology 01/2014; 5(03):153-158. DOI:10.4236/jbnb.2014.53018
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective Hemostasis interrupts bleeding from disrupted blood vessels by activating platelet aggregation and coagulation. A similar mechanism termed thrombosis generates obstructive thrombi inside diseased arteries. As a consequence of this similarity, current antithrombotic agents increase the risk of bleeding. Atherosclerotic plaques produce significant amounts of prostaglandin E2 (PGE2) which activates its receptor EP3 on platelets and aggravates atherothrombosis. We investigated whether blocking EP3 could dissociate atherothrombosis from hemostasis.Methods and ResultsInhibiting in vivo the receptor EP3 for PGE2 with the blocking agent DG-041 reduced murine thrombosis triggered by local delivery of arachidonic acid or ferric chloride on healthy arteries. Importantly, it also reduced thrombosis triggered by scratching murine atherosclerotic plaques. PGE2 was not produced at the bleeding site after tail clipping. Consistently, blocking EP3 did not alter murine tail, liver or cerebral hemostasis. Furthermore, blocking EP3 reduced murine pulmonary embolism and intensified platelet inhibition by clopidogrel leaving tail bleeding times unchanged. Human atherosclerotic plaques produced PGE2, which facilitated platelet aggregation in human blood and rescued function of P2Y12-blocked platelets. Finally, in healthy patients DG-041 reduced platelet aggregation, but did not significantly alter the cutaneous bleeding time at doses up to 8-times the dose that inhibited the facilitating effect of PGE2 on platelets. In mice, blocking EP3 inhibited atherothrombosis without affecting hemostasis and intensified efficiency of conventional antiplatelet treatment without aggravating the bleeding risk. In patients, blocking EP3 should improve the prevention of cardiovascular diseases which is currently limited by the risk of bleeding.
    Cardiovascular Research 12/2013; DOI:10.1093/cvr/cvt276 · 5.81 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this work, we study the electrochemical properties of protein layer grafted on gold electrode for C-reactive protein detection. Two CRP-antibody immobilization methods were used: the first method is based on direct physisorption of CRP-antibody onto the gold surface and the second method is based on oriented CRP-antibody with protein G intermediate layer. The two developed immunosensors were tested against CRP antigen in phosphate buffer saline solution and in human plasma. The electrochemical characterization of each immobilized layers was achieved by cyclic voltammetry and impedance spectroscopy. The morphology of the deposited biomolecules was observed by Atomic Force Microscopy and the roughness was measured. Moreover, contact angle measurement was used for wettability studies. The response of the developed immunosensors was reproducible, rapid, and highly stable and a detection limit of 100 fg/mL and 10 pg/mL antigen was observed with and without protein G respectively. The developed immunosensors was used for CRP detection in human plasma.
    Talanta 11/2013; 116:84–90. DOI:10.1016/j.talanta.2013.04.059 · 3.51 Impact Factor
  • B. Lapergue, O. Meilhac
    Archives des Maladies du Coeur et des Vaisseaux - Pratique 10/2013; 2013(221):34–36. DOI:10.1016/S1261-694X(13)70522-4

Publication Stats

3k Citations
612.73 Total Impact Points

Institutions

  • 2014–2015
    • University of La Réunion
      Saint-Denis, Réunion, Reunion
  • 2008–2014
    • University of Paris-Est
      La Haye-Descartes, Centre, France
  • 2006–2014
    • Paris Diderot University
      Lutetia Parisorum, Île-de-France, France
  • 2012–2013
    • Universidad Autónoma de Madrid
      • Enfermería de la Fundación Jiménez Díaz
      Madrid, Madrid, Spain
  • 2007–2013
    • Unité Inserm U1077
      Caen, Lower Normandy, France
    • Hôpital Bichat - Claude-Bernard (Hôpitaux Universitaires Paris Nord Val de Seine)
      Lutetia Parisorum, Île-de-France, France
  • 2002–2013
    • French Institute of Health and Medical Research
      • Institute of Genetics and Molecular and Cellular Biology
      Lutetia Parisorum, Île-de-France, France
  • 2007–2012
    • Fundación Jiménez Díaz
      • Servicio de Nefrología e Hipertensión
      Madrid, Madrid, Spain
  • 2011
    • Centre Hospitalier Universitaire de Limoges
      Limages, Limousin, France
  • 2005
    • Complutense University of Madrid
      Madrid, Madrid, Spain
  • 2004
    • University of Leuven
      Louvain, Flemish, Belgium
  • 1999–2002
    • Emory University
      • Department of Gynecology and Obstetrics
      Atlanta, GA, United States
  • 1998
    • Paul Sabatier University - Toulouse III
      • Faculté de médecine Rangueil
      Toulouse, Midi-Pyrenees, France
  • 1997–1998
    • Institut Louis Bachelier
      Lutetia Parisorum, Île-de-France, France